• Definition of craft spirits differs widely from distillery to consumer
• SBEV’s SALT Tequila strives to stand out among tequila crowd
• SALT Naturally Flavored Tequila is 100% Blue Agave, 80 proof
• Careful attention to detail results in mellow, sweet, fully developed agave flavor unmatched in industry

The definition of craft distillery varies throughout the industry; in fact, the American Craft Spirits Association (“ACSA”) has decided not to define craft but allow its members and consumers to ultimately determine their own definition (https://ibn.fm/iKQzn). Splash Beverage Group (OTCQB: SBEV), a holding company of leading portfolio of beverage brands, has defined the term with its one-of-a-kind SALT Tequila (https://ibn.fm/2Mk1J). Although the ACSA accepts that the term “craft” is in the eye of the beholder, the association notes that it thinks of craft spirits as “a product produced by a distillery who values the importance of transparency in distilling, and remains forthcoming regarding the spirit’s ingredients, distilling location, and aging and bottling process.” Splash Beverages does all of this and more through the creation of its proprietary SALT Tequila. Splash notes that its unique tequila offering relies on the focus and dedication of a boutique distillery, the skill and expertise of a tequila master, and experts trained in the art and craft of tequila. The result? The first and only tequila crafted to be enjoyed as a drink—best neat or over ice. And no wonder the beverage stands out in the tequila crowd. Each bottle of SALT Tequila is made from handpicked, 100% pure blue agave plants grown in the mountains of Jalisco. The area is one of the Mexico’s most fertile agave-growing regions, and each agave plant grows seven to 10 years before being harvested. Such attention to detail results in a mellow, sweet, fully developed agave flavor unmatched in the industry. In short, SBEV’s SALT Tequila represents years of deliberate determination, inspiring innovation, and invaluable expertise culminating together in the clear, smooth, sweet and natural flavor that has come to define one of the industry’s finest tequila offerings. Specializing in manufacturing, distributing, sales and marketing of various beverages across multiple channels, Splash operates in both the alcoholic and nonalcoholic beverage segments, allowing it to leverage efficiencies and dilute risk. The company’s business strategy is to quickly develop and accelerate pre-existing brands to exit for cash events. The company’s management team has invaluable expertise and insight, and the company strives to identify brands it perceives to have highly visible preexisting brand awareness or pure category innovation. Specifically, the company look for brands and products that are on trend and deliver natural quality, health benefits, freshness and refreshment within their beverages. The company looks to maintain highest performance standards and focus on execution as it works with distributors and retail partners to achieve and exceed all goals. In addition, the company offers support for members of the U.S. armed forces, first responders and health-care professionals. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• FingerMotion has forged strong relationships with the three largest telecommunication companies in China
• The relationships have given FNGR access to subscriber data, allowing it to test its proprietary data analytics algorithms in real-time
• The algorithms, created by FingerMotion’s Big Data Insights Division, leverage raw mobile data to create a user persona

A technological company, FingerMotion (OTCQX: FNGR) has evolved over the years. What began as a mobile gaming company, launched in 2016, morphed into a mobile payment and recharge service provider in 2018, offering these services to China Unicom’s (NYSE: CHU) customers. That same year, FNGR was awarded a contract to become CHU’s big data analysis partner, with success from this agreement leading to a similar arrangement with China Mobile the following year. In 2019, the company began offering mobile payment and recharge services to the users of both China Mobile and China Telecom (NYSE: CHA). “We began by forging relationships with the three telecoms in China, China Telecom, China Mobile and China Unicom. By building up our relationships and providing consistent and dependable service, they have, in turn, given us unprecedented access to their respective user bases. This allows us to target telecom users with innovative products in an unobtrusive manner,” FingerMotion CEO Martin Shen said in a presentation during the Emerging Growth Conference (https://ibn.fm/Bc3iN). The relationships with the three telecommunication companies, whose combined subscriber base as of 2020 stood at over 1.5 billion users (https://ibn.fm/YpyFF), helped FingerMotion venture into the big data insights business. Shen, who described the company’s Big Data Insights division as the most exciting, noted in a separate webinar address (https://ibn.fm/eX8TW) that this division comprises a team of data scientists and actuaries who have developed proprietary algorithms to predict human behavior. FNGR then leverages its relationship with the telecommunication juggernauts to run these algorithms in real-time and off a secure database. “We’re well-positioned to capitalize on the continually growing power of mobile data, transforming telecommunication signals into data blocks and integrating them with a host of external data and auxiliary information for mining and analyzing behavioral insights,” Shen added. According to Shen, the company aims to create an integrated data ecosystem through technology and innovation. To do this, it intends to start with offering enhanced efficiency and user experience in mobile communications and subsequently extend the scope to deeper consumer behavior analytics, anchored on a comprehensive set of high quality and relevant mobile user data. This approach will enable the company to meet the needs of its customers through products and partnerships. FingerMotion, which intends to ultimately offer products for the insurance, healthcare and finance sectors, is initially focusing on insuratech. This focus was evident in January when the company announced it has partnered with Pacific Life Re-insurance, in effect becoming its data provider. Notably, the partnership will extend beyond simply providing data as FNGR will also offer behavioral analytics, which Shen described as “brief insights into human nature itself.” To generate the data insights, FingerMotion’s algorithm will rely on raw mobile data, including rudimentary information such as age, gender and place of residence. The algorithm will overlay this basic tier with a person’s geospatial information, such as places they have visited, to learn about the person and what they do throughout the day. Finally, it will utilize the individual’s internet usage, as well as call and SMS data. However, it’s important to remember in all of this that the personal information is scrubbed, and only demographic information is used to create the data packets that personify the mobile data. By superimposing the four tiers, the algorithm can create anonymous data packets that personify the mobile data, describing the phone usage with parameters such as their occupation, number of hours they work, fitness level and more. FingerMotion is clearly leveraging raw mobile data to offer a big data asset that can significantly help companies. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions
• The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas
• Tryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp’s psilocybin product

Following a year in which a global pandemic led to heightened concerns about individuals’ mental well-being while navigating the health emergency’s effects on society (https://ibn.fm/YGqDb), proponents of psychedelic medicine development programs gained stronger allies in legislative as well as commercial arenas (https://ibn.fm/sUosF).

Pharmaceutical developer Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is making its own inroads with using psychedelics for medicinal purposes, conducting clinical trials in preparation for planned monetization of its two drug platforms — the mushroom-based psychedelic compound, psilocybin, for treating fibromyalgia, eating disorders and chronic pain conditions, and the cancerous tumor-inhibiting drug razoxane for treating soft tissue sarcomas.

Tryp was founded in 2019 and recently released its Q2 interim financial results for the three and six month periods ended February 28, 2021, showing completion of the company’s initial public offering (“IPO”) that brought in more than $5 million through the aggregate issuance of more than 20 million units in December (https://ibn.fm/yHsVj).

During the reporting period, Tryp also added three leading experts to its Scientific Advisory Board and named a new CEO and a new CFO. The report also noted advancements with Tryp’s synthetic psilocybin manufacturing program and a new collaboration with the University of Florida on clinical trial activities for eating disorders.

A series of reports and studies indicate that the pandemic has likely fueled a rise in problems associated with eating disorders, including one finding that there has been a 70 percent rise in mental health support referrals for eating disorders among youth during the pandemic (https://ibn.fm/nI4Gb). Two new studies found a correlation between the COVID-19 pandemic and post-traumatic stress disorder (“PTSD”) symptoms among patients with eating disorders (https://ibn.fm/EEbEp).

Pediatric physician Jennifer Miller, M.D. of the University of Florida is serving as the principal investigator for a Phase 2a clinical trial for eating disorders using Tryp’s psilocybin product.  Dr. Miller is a leading expert in certain eating disorders including binge eating and hyperphagia.  The clinical trial that she is leading is expected to significantly advance Tryp’s work in evaluating the safety, pharmacokinetics and efficacy of TRP-8802, Tryp’s key product under its Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program.

“There are currently no approved drugs and only limited options to treat patients with rare over-eating disorders,” Miller stated in a news release announcing the collaboration (https://ibn.fm/8jecT). “I’m excited to work with the Tryp team to explore the use of psilocybin as a new paradigm to treat symptoms associated with this devastating medical disease.”

In the end, Tryp’s aim is to develop clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways. A provisional patent filed in March 2021 establishes the company’s IP for the formulation, delivery and dosing of psychedelics to produce a potential reduction in the time spent by patients in the dissociative state, and Tryp plans to submit additional provisional patents this year related to the manufacturing and formulating of psilocybin, among other innovations.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• RYAH Group to start trading on Canadian Securities Exchange following a transaction involving a triangular merger
• RYAH Group is digital health care analytics and technology company developing innovative solutions for the plant-based medical industry
• RYAH is poised for growth as the world transitions to remote health at an accelerated pace due to the pandemic

RYAH Group (formerly known as Prime Blockchain Inc.) will start trading on the Canadian Securities Exchange under the ticker symbol “RYAH” today (https://ibn.fm/Z6gZj). The New York-based digital health care analytics and technology company is focused on the development and commercialization of innovative technology, including software and hardware, for the plant-based medical industry. The upcoming listing follows the Company’s previously announced closing of a reverse takeover transaction with Potbotics Inc. The transaction included a triangular merger between RYAH Group (formerly Prime Blockchain, Inc.), Potbotics, and a wholly-owned Florida subsidiary of the Company incorporated to complete the transaction (https://ibn.fm/EhuYh). For companies making a public market debut, traditional IPOs were dominant until 2019, but novel forms of going public stole the limelight in 2020. This includes reverse mergers, a transaction where a private company buys out shares to control the public company. The two entities merge, which effectively makes the private company become public (https://ibn.fm/vA0wf). “This is another major step in our journey in transforming patient care through our remote, connected devices and data analytics, to help unearth breakthrough discoveries that will reshape our understanding of plant-based medicines, nutraceuticals and beyond. We continue to live our mission and vision of delivering cutting-edge innovation to advance digital care and to provide shareholder and consumer value in all of our products and services,” said Gregory Wagner, CEO of RYAH Group Inc. As an emerging company, RYAH Group Inc. has been committed to leveraging its know-how in predictive analytics to establish itself as a leader in delivering innovative, user-friendly IoT devices in the plant-based medical industry. The Company applies novel AI-powered analytics to pioneer a suite of vertically integrated technologies to facilitate data collection across the medical plant lifecycle, offering users added control over their health and wellness. RYAH Group Inc’s powerful artificial intelligence platform collects and correlates HIPAA-compliant medical data to assist doctors and patients in personalizing therapeutic treatments to better predict treatment outcomes. The data aggregation is also relevant for research institutions, pharmacies, clinics, growers, dispensaries and licensed processors to monitor and manage plant-based medicine and other formulation effects on patients. RYAH Group Inc’s commitment to advance the transition to remote digital care and data analytics in patient treatments appears to be well-timed. The last year saw the world shifts to everything online — health care included. With so many growth opportunities opened up due to the pandemic, the Company appears poised to solidify its position in the digital health care analytics market with the upcoming listing. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• As vaccine rollout continues nationwide, pent-up demand is expected to burst, fueled by massive reserves of excess savings
• Economists expect record consumer spending over the next two quarters, at levels not seen in the past 70 years
• SHRG seizes lucrative market opportunities, leverages business model to enter the travel sector

Sharing Services Global (OTCQB: SHRG), a publicly traded company specializing in direct selling and other sectors, has once again demonstrated its ability to make quick moves as market forces shift. The company has announced plans to penetrate the travel sector as consumers should be eager to travel again soon. Travel appears on the verge of a boom, and SHRG looks poised to take its share of this growth opportunity. As more and more people get the COVID-19 vaccine, businesses are trying to determine what consumer spending will look like in the future — and the outlook seems promising. The economy appears on the cusp of a major boom cycle that economists believe could last (https://ibn.fm/xpMVK). Since the beginning of the pandemic, Americans have accumulated massive reserves of excess savings, estimated by Bloomberg Economics at a staggering $1.7 trillion in January this year. Although Americans’ worries about health and safety will likely linger, there’s pent-up demand due to this enormous amount of resources. Consumer spending over the next two quarters is expected to be the strongest in the last 70 years, and leisure expenditures may lead the way. As the economy reopens, consumers are likely to binge on so-called “revenge spending” on the things they were denied over the last year, such as travel, entertainment, and dining (https://ibn.fm/wMGt3). The travel sentiment is clearly on the upswing — recent numbers released by the U.S. Travel Association show that in January 2020, 63% of Americans had plans to travel over the next six months, up from 57% in mid-December. After a year of lockdowns due to the pandemic, consumer sentiment is picking up as the rollout of the COVID-19 vaccine gathers steam across the country (https://ibn.fm/VPqUO). Air travel is surging, and hotel bookings appear to be on the path of recovery (https://ibn.fm/KrvnM). Quick to recognize market shifts as they start to emerge, SHRG is entering into the travel industry to capitalize on this swelling opportunity that is likely to endow the previously decimated travel sector. The company plans to leverage its proven business model to provide superior travel products and experiences through broad access to savings and exclusive benefits. The travel company, one of SHRG’s subsidiaries, is intended to be an exclusive travel club offering a “Passport to Happiness” to brand partners and customers. Confident that now is the most opportune time to make this strategic move, as the next months will likely see people rushing to start traveling again, Sharing Services Global appears poised to capitalize on the major shift in consumer spending. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Production underway for 25,000 vape cartridges using PULL full spectrum oil formulations, including Super Lemon Haze, Grand Daddy Purple and Girl Scout Cookies/GSK
• Company estimates retail sales revenue for this production run will be approximately $750,000
• 60% of respondents in StatCan’s Canadian 2020 Cannabis Survey that used vaporizer for cannabis in the last 12 months used oil/extracts

“Cannabis 2.0,” the colloquial term for legalization of cannabis derivatives in Canada late in 2019, represented the outset of new trends in how people consume cannabis products with the accessibility of goods like drinks and vape products. While some companies have devoted considerable resources to in-house extraction technologies, the market is still relatively scant for certified extractors that can meet demand for concentrates from cannabis biomass. This is the focus of Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), which just experienced a milestone moment with commencement of production of 25,000 vape cartridges for the Canadian retail market.

The Company operates a 10,000 sq. ft., Health Canada licensed facility in Pemberton, British Columbia, constructed to EU-GMP standards, aligning Pure Extracts for international distribution. The bespoke facility houses equipment for cutting-edge CO2 and ethanol extraction capabilities and processes, with phase 2 plans to build-out underutilized space into an R&D and production center for functional and psychedelic mushrooms. The Company intends to become a go-to company in extraction for multiple markets, with capacity to process both cannabis and hemp biomass as well as functional and psychedelic mushrooms in order to satisfy clients’ needs.

In Statistic Canada’s Canadian 2020 Cannabis Survey that included nearly 11,000 respondents, a new question was posed. Of the people that used a vaporizer to ingest cannabis in the last 12 months, 60% said they used cannabis oil/extract (https://ibn.fm/czeYf).

Demand for Pure Extracts’ Pure Pulls branded 510 Vape cartridges is strong in the provincial markets in Canada. 510 cartridges are the most popular on the market today and so named to describe the threading that attaches the cartridge to the vape battery. The Company has teamed up with a leading global manufacturer of premium cartridges that dovetails with Pure Extracts’ expectations for the highest quality components and performance when paired with its oil concentrates.

The production plans call for the cartridges to be filled with selections from the Company’s proprietary library of more than 30 full spectrum oil (“FSO”) formulations, including Super Lemon Haze, Grand Daddy Purple and Girl Scout Cookies/GSK. Management estimates retail sales from the production run to be approximately $750,000.

“We are excited about preparing to ship our first vape cart orders to the provincial distribution channels,” said Pure Extracts CEO Ben Nikolaevsky in a recent press release (https://ibn.fm/qCNB6). “We have created the high quality FSO vape products that consumers now demand and believe that we will quickly build brand loyalty with both legacy and new entrants in the vape space.”

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• McKinsey & Company notes that portfolio model is growing in popularity amongst companies and investors
• HLTT recently acquired precision oncology company Varian Biopharma
• Report shows that more than $5.5 billion in capital has been raised in past six years by companies with biotech portfolio models

An emerging trend in biotechnology involves abandoning a single shot on goal approach in favor of a broader strategy with different portfolio companies under one umbrella. The old incubator approach with a new flare, the trend involves a portfolio manager utilizing a variety of skillsets to assemble a group of subsidiaries, each committed to a different specialty or drug program. It can be a de-risking methodology that simultaneously amplifies the upside of the parent company, and biotech players like Healthtech Solutions (OTC: HLTT) have pivoted to this model, primarily through its recent acquisition of Varian Biopharmaceuticals (https://ibn.fm/ZLSAj). With the buyout of Varian Biopharma, Healthtech expanded its portfolio to three distinct healthcare subsidiaries. MediScan, Inc. has developed disruptive technology that converts 2D images from a portable ultrasound machine into 3D, high-definition images, a leap forward in imaging to improve diagnoses by providing point-of-care imaging on par with X-rays, MRIs and CT scans. The company’s RevHeart unit is advancing critical research into the treatment of COVID-related heart muscle injury. As noted in a recent report by McKinsey & Company, the model is growing in popularity amongst companies and investors. Firms like BridgeBio Pharma (NASDAQ: BBIO) and Biohaven Pharmaceutical (NYSE: BHVN) are two blue chips operating under the central-management-with-multiple-subsidiaries structure, demonstrating the strong investor interest. All told, the report shows that more than $5.5 billion in capital has been raised in the past six years by companies with biotech portfolio models (https://ibn.fm/AUNNS). Varian Biopharma, which will be housed as a new Healthtech Oncology, Inc. subsidiary, is a precision oncology company specializing in the development of atypical protein kinase C iota, or aPKCi, inhibitors for different tumor types. Varian Bio’s two lead candidates are still being prepared for clinical trials. VAR-101 is a topical formulation for basal cell carcinoma, the most common type of skin cancer, affecting about 4.3 million Americans each year (https://ibn.fm/jK1ta). VAR-102 is an experimental oral drug that will be tested against a battery of resilient tumors where research has shown aPCKi inhibition could be an effective pathway, including pancreatic, colorectal and non-small cell lung cancers (“NSCLC”). A new approach in precision oncology, aPKCi inhibition innovates through regulation of transcription factors such as GLI-1 and K-RAS—proteins known to be integral in cancer pathogenesis. Varian appears to be on the leading edge, as K-RAS G12C is considered the most prevalent emerging biomarker in NSCLC (https://ibn.fm/7Brip). Investors from small retail to institutions seem to value the new model over the traditional straight-line approach of biotech. The rewards could be great in the traditional model, but with the odds weighing in only around 5% at best that any pre-clinical biotech asset would make it to launch, the risks are equally high. The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment. Again, that’s an appetizing part of the basket model. “The fact that [Varian Bio is] developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is,” said Healthtech Solutions Chairman and CEO David Rubin in a statement disclosing the acquisition. “Precision oncology is an exciting field and we’re thrilled to be a part of it,” he added. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• SRAX held first-ever virtual Sequire Cannabis Conference on April 20, 2021
• Event featured over 40 cannabis company presentations, keynote appearances by Steve DeAngelo, Dr. Sue Sisley, Emily Paxhia, Steven Hawkins, Dr. Jeffrey Chen
• Sequire provides data analytics tools that help public companies track investor activity, such as investor tracking, warrant management, shareholder surveys
• Sequire has grown to over 3 million users across 183 companies since 2019

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently held its first-ever virtual Sequire Cannabis Conference on April 20, 2021 (https://ibn.fm/nr7Pd). Nearly one million active small-cap investors were invited to the event, which featured presentations by over 40 cannabis companies along with keynote appearances by prominent industry experts such as Steve DeAngelo, Dr. Sue Sisley, Emily Paxhia, Steven Hawkins, and Dr. Jeffrey Chen. The cannabis industry has undergone seismic shifts in the last decade that included the publication of notable scientific studies and extensive research reviews (https://ibn.fm/GbwCt), along with legalization in several states (https://ibn.fm/dT9BO). The industry has since exploded with thousands of new companies in various sectors, including plant genetics cultivation, product development, e-commerce portals and physical dispensaries across the United States. Presenting at the Cannabis Conference were prominent industry leaders such as Steve DeAngelo, a lifelong activist, entrepreneur and co-founder of Harborside, The Arcview Group, The Last Prisoner Project non-profit organization, and the Radio Free Cannabis podcast. He was interviewed by Emily Paxhia, an investment expert who has reviewed thousands of companies in the cannabis space in addition to working with numerous founders in various capacities. Also featured at the conference were interviews with Dr. Sue Sisley and Steve Hawkinsby Dr. Jeff Chen, co-founder and CEO of Radicle Science, and Founder and Director of the UCLA Cannabis Research Initiative. Sisley is an Arizona-based physician, President of Scottsdale Research, and Principal Investigator for FDA-approved randomized controlled trials. Hawkins is the President & CEO of the United States Cannabis Council and Executive Director of the Marijuana Policy Project. The Cannabis Conference is one of many industry-specific events SRAX plans to host on Sequire this year. Besides event management, the platform empowers public companies with data analytics tools that include investor tracking, warrant management, and shareholder surveys. Since its 2019 inception, the platform has grown to include over 3 million users across 183 public companies and is rapidly becoming the premier analytics platform in the investment space (https://ibn.fm/jBwJf). SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. Replays of SRAX’s Sequire Cannabis Conference can be accessed at https://cannabis-conference.mysequire.com/. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Beijing-based Infobird has built rich experience in the customer engagement industry that covers SaaS solutions such as cloud call center, intelligent telemarketing, AI Chatbots, and has now closed its IPO on the NASDAQ exchange.
• Infobird’s artificial intelligence (“AI”) solutions help clients to minimize costs and maximize potential revenues.
• The company’s self-developed cloud-native architecture and patented AI technologies work with a no-code development platform to help companies focus their efforts and financial outlays where they are most needed.

B2B artificial intelligence (“AI”) solutions company Infobird (NASDAQ: IFBD) is building next-level operations in tandem with the Beijing, China-based company’s April 20 IPO debut on The Nasdaq Capital Market (https://ibn.fm/TPyf7). Infobird has built a reputation as a premier provider of customer engagement SaaS solutions in China that use automated and smart solutions to maximize value for its clients through reduced corporate costs that don’t impinge on the clients’ ability to generate and increase revenues. The company’s self-developed cloud cloud-native architecture and patented AI technologies, for example, work with a no-code development platform that allows enterprise-building companies to focus on managing their operations as they know best, while relying on the technological expertise of application builders for only the most necessary development efforts, likewise enabling the automation of AI-empowered call center features to handle many of the routine and repetitive functions that human personnel might otherwise be needed for in large numbers. Infobird is one of the first enterprises to apply intelligent technology to customer service industry. Over the past decade, the company has built a client base of over 10,000 paid user accounts from 358 customers in finance, education, public services, consumer products and health care. While its primary focus is on key corporations in the finance industry, it has served clients from other industries as well, such as e-commerce giant Alibaba (NYSE: BABA). As one of the leading software-as-a-service (SaaS) providers in China, Infobird uses a highly successful business model in which centrally hosted software is licensed to customers via a subscription plan that not only generates recurring revenue but also opens wide channels of ancillary revenue streams. The SaaS sector has experienced significant growth in recent years and China is now the second-largest market in the world for cloud infrastructure spending. During the past 20 years, Infobird has continually expanded its technological boundaries, acknowledging that the “intelligence” of intelligent customer service cannot be realized by a single technology and must instead depend on the interaction and integration of various technological systems. With the explosion of big data, AI and other technologies, Infobird has continuously integrated voice recognition, intelligent interaction and other technologies into its product research and development. By integrating big data, AI, cloud computing, 5G and other technologies, the company can provide smart and value-added solutions for all customer engagement processes and thus empower the enterprises to better interact with their customers, to reduce costs for the operation and ultimately to increase sales revenue. For more information, visit the company’s website at www.Infobird.com/en/index.html NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways
• The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas)
• Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that offer increased efficacy and reduced risk of abuse or addiction
• The company’s management team has decades of experience in the life sciences industry, including the pharmaceutical and biotechnology markets
• Oncology therapeutics are expected to account for roughly 30% of all drug sales by 2024, representing a total market valued at approximately $200 billion

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN(TM) Program

Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN(TM) program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica(R)), Duloxetine (Cymbalta(R)) and Milnacipran (Savella(R)), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (“YPO”) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF